Skip to main content
. 2015 Apr;100(4):541–547. doi: 10.3324/haematol.2014.116269

Figure 2.

Figure 2.

The waterfall plot shows the best response at time of assessment of the 12 available patients (A). The shading of the bars indicates the different drug level cohorts: white is cohort 1 (5 mg), light gray cohort 2 (7.5 mg) and dark gray cohort 3 (10 mg). Black frames represent serum M protein, black spotted frames total IgA (in cases without measurable serum M protein) and a gray frame represents urinary M protein as a disease marker. Seven patients had clinical benefit, achieving stable disease (#), minor response (ǂ) or partial response (§). Five patients showed progressive disease as defined by IMWG criteria (*), early withdrawal due to hyperviscosity (**) or growing spinal tumor (***). The everolimus blood levels of patients (average of all measurements in a particular patient) grouped according to the best clinical status achieved (B). Although the patient with a partial response had the second highest blood level, the data show no obvious correlation between drug level and efficacy as indicated by comparable median blood levels for all groups [white diamond: dose level 1 (5 mg daily), gray quadrangle: dose level 2 (7.5 mg daily), dark gray circle: dose level 3 (10 mg daily)]; PD=progressive disease, SD=stable disease, MR= minor response, PR= partial response). Bone marrow was stained for the phosphorylated forms of mToR (C) and 4EBP1 (D) demonstrating a wide variety in activation of the pathway in plasma cells at baseline (dark gray bars). However, under treatment phosphorylation of mToR was abolished in all investigated samples (last biopsy: light gray bars) whereas activation of the downstream target 4EBP1 was only slightly decreased (n.d.= not done).